Relationship between HOPX expression and efficacy of neoadjuvant chemotherapy for patients with locally advanced breast cancer

doi:10.3760/cma.j.issn.1007-1245.2024.19.026

Abstract

Abstract:

Objective　To investigate the relationship of the expression of homologous domain protein homeobox (HOPX) and the methylation of HOPX in peripheral blood with the efficacy of neoadjuvant chemotherapy for patients with locally advanced breast cancer. Methods　The data of 129 patients admitted to Xianyang Central Hospital were analyzed. They were (50.69±5.48) years old. There were 71 cases of high differentiation and 58 cases of low differentiation. There were 48 cases of stage ⅡB and 81 cases of stage Ⅲ. Eighty-seven cases had lymph node metastasis. According to the efficacy of neoadjuvant chemotherapy, they were divided into pathological complete response (pCR) and non-pCR. The expression of HOPX and the methylation level of HOPX in peripheral blood in the patients before neoadjuvant chemotherapy were detected. The relationship of HOPX expression in cancer tissue and HOPX methylation rate in peripheral blood with the pathological features of the patients with locally advanced breast cancer was analyzed. The factors influencing the efficacy of neoadjuvant chemotherapy were analyzed. The relative expression of HOPX mRNA in cancer tissue and the methylation rate of HOPX in peripheral blood in predicting the efficacy of neoadjuvant chemotherapy for the patients were analyzed. t and χ² tests were used. The Cox proportional risk model was used for the influencing factors. The receiver operating characteristic curve (ROC) was used to evaluate the prediction efficacy. Results　The relative expression level of HOPX mRNA in the cancer tissue was higher than that in the adjacent tissue [(1.97±0.32) vs. (1.13±0.21); P<0.05]. The relative expression level of HOPX mRNA and the methylation rate of HOPX in peripheral blood of the patients with low differentiation, stage Ⅲ, and lymph node metastasis were higher than those of the patients with middle and high differentiation, stage ⅡB, and no lymph node metastasis [(2.19±0.37) vs. (1.79±0.32), (2.23±0.39) vs. (1.53±0.26), (2.14±0.35) vs. (1.62±0.28), 81.03% (47/58) vs. 56.34% (40/71), 75.31% (61/81) vs. 54.17% (26/48), and 73.56% (64/87) vs. 54.76% (23/42); all P<0.05]. The Cox regression analysis showed that tumor stage (RR=5.557, 95%CI 2.286-13.505), differentiation degree (RR=5.360, 95%CI 2.206-13.027), relative expression level of HOPX mRNA (RR=4.455, 95%CI 1.833-10.827), and HOPX methylation rate (RR=4.362, 95%CI 1.795-10.602) were the factors affecting the efficacy of neoadjuvant chemotherapy for the patients (all P<0.05). The ROC analysis results showed that the relative expression level of HOPX mRNA combined with HOPX methylation rate had AUC in predicting the efficacy of neoadjuvant chemotherapy for the patients than single one (0.894 vs. 0.774 and 0.894 vs. 0.768). Conclusions　The relative expression level of HOPX mRNA in cancer tissue and the methylation rate of HOPX in peripheral blood of patients with locally advanced breast cancer are closely related to pathological characteristics and the efficacy of neoadjuvant chemotherapy. The combination of the two can predict the efficacy of neoadjuvant chemotherapy well.

Key words:

Breast cancer, Homeodomain-only protein homeobox, Pathological features, Neoadjuvant chemotherapy, Curative effect

摘要：

目的　探讨局部晚期乳腺癌组织中同源域蛋白同源盒（HOPX）表达及外周血HOPX甲基化与新辅助化疗疗效的关系。方法　回顾性分析2020年1月至2023年10月咸阳市中心医院收治的129例局部晚期乳腺癌患者的资料，年龄（50.69±5.48）岁；中高分化71例、低分化58例；ⅡB期48例、Ⅲ期81例；淋巴结转移87例。根据新辅助化疗疗效分为病理完全缓解（pCR）、非pCR。检测患者新辅助化疗前癌组织、癌旁组织中HOPX表达及外周血HOPX甲基化水平。分析局部晚期乳腺癌患者癌组织中HOPX表达、外周血HOPX甲基化率表达与病理特征关系，影响化疗疗效的因素，癌组织中HOPX mRNA相对表达量、外周血HOPX甲基化率预测局部晚期乳腺癌患者新辅助化疗疗效的价值。采用t检验、χ²检验，影响因素用Cox比例风险模型，受试者操作特征曲线（ROC）评估预测效能。结果　癌组织中HOPX mRNA相对表达量高于癌旁组织［（1.97±0.32）比（1.13±0.21），P<0.05］。低分化、Ⅲ期、有淋巴结转移的患者癌组织中HOPX mRNA相对表达量、外周血HOPX甲基化率分别高于中高分化、ⅡB期、无淋巴结转移者［（2.19±0.37）比（1.79±0.32）、（2.23±0.39）比（1.53±0.26）、（2.14±0.35）比（1.62±0.28），81.03%（47/58）比56.34%（40/71）、75.31%（61/81）比54.17%（26/48）、73.56%（64/87）比54.76%（23/42），均P<0.05］。Cox回归分析显示：肿瘤分期（RR=5.557，95%CI：2.286～13.505）、分化程度（RR=5.360，95%CI：2.206～13.027）、HOPX mRNA相对表达量（RR=4.455，95%CI：1.833～10.827）、HOPX甲基化率（RR=4.362，95%CI：1.795～10.602）是影响局部晚期乳腺癌患者新辅助化疗疗效的因素（均P<0.05）。ROC分析结果显示，HOPX mRNA相对表达量联合HOPX甲基化率预测局部晚期乳腺癌患者新辅助化疗疗效的曲线下面积高于单独预测（0.894比0.774比0.768）。结论　局部晚期乳腺癌患者癌组织中HOPX mRNA相对表达量、外周血HOPX甲基化率与病理特征、新辅助化疗疗效相关，二者联合预测患者新辅助化疗疗效的效能良好。

关键词:

乳腺癌, 同源域蛋白同源盒, 病理特征, 新辅助化疗, 疗效

Li Chong, Wang Fei.

Relationship between HOPX expression and efficacy of neoadjuvant chemotherapy for patients with locally advanced breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(19): 3296-3301.

李冲王飞.

HOPX表达与局部晚期乳腺癌新辅助化疗疗效的关系 [J]. 国际医药卫生导报, 2024, 30(19): 3296-3301.

References

[1] Scudeler MM, Manóchio C, Braga Pinto AJ, et al. Breast cancer pharmacogenetics: a systematic review[J]. Pharmacogenomics, 2023,24(2):107-122. DOI: 10.2217/pgs-2022-0144.
[2] Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer[J]. Breast, 2022,62 Suppl 1:S12-S16. DOI: 10.1016/j.breast.2022.01.006.
[3] Gluz O, Nitz U, Kolberg-Liedtke C, et al. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial[J]. Clin Cancer Res, 2022,28(22):4995-5003. DOI: 10.1158/1078-0432.CCR-22-0482.
[4] Gu J, Tong T, He C, et al. Deep learning radiomics of ultrasonography can predict response to neoadjuvant chemotherapy in breast cancer at an early stage of treatment: a prospective study[J]. Eur Radiol, 2022,32(3):2099-2109. DOI: 10.1007/s00330-021-08293-y.
[5] Blaine-Sauer S, Samuels TL, Yan K, et al. The protease inhibitor amprenavir protects against pepsin-induced esophageal epithelial barrier disruption and cancer-associated changes[J]. Int J Mol Sci, 2023,24(7):6765. DOI: 10.3390/ijms24076765.
[6] Mao N, Shi Y, Lian C, et al. Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on contrast-enhanced spectral mammography[J]. Eur Radiol, 2022,32(5):3207-3219. DOI: 10.1007/s00330-021-08414-7.
[7] Bourque J, Kousnetsov R, Hawiger D. Roles of Hopx in the differentiation and functions of immune cells[J]. Eur J Cell Biol, 2022,101(3):151242. DOI: 10.1016/j.ejcb.2022.151242.
[8] Jin Y, Arimura H, Cui Y, et al. CT image-based biopsy to aid prediction of HOPX expression status and prognosis for non-small cell lung cancer patients[J]. Cancers (Basel), 2023,15(8):2220. DOI: 10.3390/cancers15082220.
[9] Pavlova O, Lefort K, Mariotto A, et al. HOPX exhibits oncogenic activity during squamous skin carcinogenesis[J]. J Invest Dermatol, 2021,141(10):2354-2368. DOI: 10.1016/j.jid.2020.04.034.
[10] Lima EU, Rubio IGS, Da Silva JC, et al. HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance[J]. Endocr Connect, 2018,7(12):1333-1342. DOI: 10.1530/EC-18-0380.
[11] 吴楠,简晓清,吴梦婕. 同源域蛋白同源盒在胃癌组织的表达及其临床意义[J]. 中华实验外科杂志,2023,40(2):215-218. DOI:10.3760/cma.j.cn421213-20220719- 01223.
[12] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志,2019,29(8):609-679. DOI:10.19401/j.cnki.1007-3639.2019.08.009.
[13] Hagenaars SC, de Groot S, Cohen D, et al. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer[J]. Int J Cancer, 2021,149(5):1181-1188. DOI: 10.1002/ijc.33700.
[14] Ooizumi Y, Katoh H, Yokota M, et al. Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer[J]. Oncotarget, 2019, 10(57):5906-5918. DOI: 10.18632/oncotarget.27187.
[15] Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol, 2021,39(13):1485-1505. DOI: 10.1200/JCO.20.03399.
[16] Provenzano E. Neoadjuvant chemotherapy for breast cancer: moving beyond pathological complete response in the molecular age[J]. Acta Med Acad, 2021,50(1):88-109. DOI: 10.5644/ama2006-124.328.
[17] Zhang H, Barner JC, Moczygemba LR, et al. Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017[J]. Breast Cancer Res Treat, 2022,193(3):695-705. DOI: 10.1007/s10549-022-06604-5.
[18] Wolf DM, Yau C, Wulfkuhle J, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies[J]. Cancer Cell, 2022,40(6):609-623.e6. DOI: 10.1016/j.ccell.2022.05.005.
[19] 张玉,袁权,汤增辉,等. ADC值联合18F-FDG PET/CT最大标准摄取值对乳腺癌新辅助化疗疗效的预测价值[J]. 放射学实践,2022,37(5):550-555. DOI:10.13609/j.cnki.1000-0313.2022.05.003.
[20] 贺春燕,张啸飞,刘兵,等. 动态增强MRI预测乳腺癌新辅助化疗后病理完全缓解的准确性[J]. 中国临床医学影像杂志,2022,33(2):96-100. DOI:10.12117/jccmi.2022.02.005.
[21] Tanaka Y, Kosaka Y, Waraya M, et al. Differential prognostic relevance of promoter DNA methylation of CDO1 and HOPX in primary breast cancer[J]. Anticancer Res, 2019,39(5):2289-2298. DOI: 10.21873/anticanres.13345.
[22] Georgy SR, Rudiatmoko DR, Auden A, et al. Identification of a novel GRHL3/HOPX/Wnt/β-catenin proto-oncogenic axis in squamous cell carcinoma of the esophagus[J]. Cell Mol Gastroenterol Hepatol, 2023,15(5):1051-1069. DOI: 10.1016/j.jcmgh.2022.11.009.
[23] 游庆华,徐冬香,叶慧英,等. 乳腺癌患者血清中HOPX甲基化水平与CA15-3和CA125水平的相关性[J]. 热带医学杂志,2021,21(5):613-617. DOI:10.3969/j.issn.1672-3619.2021.05.019.
[24] 侯保森,徐培坤,王斌,等. 脑胶质瘤患者肿瘤组织和外周血HOPX基因甲基化的检测[J]. 安徽医科大学学报,2018,53(3):428-432. DOI:10.19405/j.cnki.issn1000-1492.2018.03.021.
[25] Pavlova O, Lefort K, Mariotto A, et al. HOPX exhibits oncogenic activity during squamous skin carcinogenesis[J]. J Invest Dermatol, 2021,141(10):2354-2368. DOI: 10.1016/j.jid.2020.04.034.